0001140361-22-000828.txt : 20220106 0001140361-22-000828.hdr.sgml : 20220106 20220106161353 ACCESSION NUMBER: 0001140361-22-000828 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220106 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220106 DATE AS OF CHANGE: 20220106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kinnate Biopharma Inc. CENTRAL INDEX KEY: 0001797768 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824566526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39743 FILM NUMBER: 22514970 BUSINESS ADDRESS: STREET 1: 11975 EL CAMINO REAL, STE 101 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 8582994699 MAIL ADDRESS: STREET 1: 11975 EL CAMINO REAL, STE 101 CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 brhc10032606_8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K



CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported)
January 6, 2022



KINNATE BIOPHARMA INC.
(Exact name of registrant as specified in its charter)



Delaware
001-39743
82-4566526
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
3611 Valley Centre Drive, Suite 175
San Diego, CA 92130
(Address, including zip code, of Registrant’s principal executive offices)
 
(858) 299-4699
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)


 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, par value $0.0001 per share
 
KNTE
 
The Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02.
Results of Operations and Financial Condition.

The information set forth in Item 8.01 is hereby incorporated by reference.

Item 8.01.
Other Events.

On January 6, 2022, Kinnate Biopharma Inc. issued a press release announcing a corporate update, expected milestones for 2022 and its cash, cash equivalents and investments balance as of December 31, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01.
Financial Statements and Exhibits.

(d)
Exhibits.

 
Exhibit No.
 
Description
       
   
Press Release dated January 6, 2022.
       
 
104
 
Cover page interactive date file (embedded within the inline XBRL document).


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
KINNATE BIOPHARMA INC.
     
 
By:
/s/ Nima Farzan
   
Nima Farzan
President and Chief Executive Officer
     
Date: January 6, 2022
 



EX-99.1 2 brhc10032606_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1
 

Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones

Announces proof-of-concept preclinical data demonstrating activity of KIN-2787 in
NRAS-mutant melanoma

Provides update on ongoing KN-8701 trial with expansion to include patients with NRAS-mutant melanoma in monotherapy and initiation of a combination portion with binimetinib planned for first half of 2022

Announces planned initiation of Phase 1 trial of KIN-3248 for first half of 2022 subject to IND clearance by the FDA

Updated cash, cash equivalents and investments of approximately $324.9 million as of December 31, 2021, exclusive of Kinnjiu’s (its China joint venture) cash, expected to fund current operations into second half of 2023
 
SAN FRANCISCO and SAN DIEGO, Calif. – January 06, 2022 – Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced continued advancement of the company’s ongoing clinical trial, KN-8701, to include patients with NRAS-mutant melanoma and planned 2022 milestones for its product candidates, including KIN-2787, an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors. The company also updated its cash position as of December 31, 2021.

“We have built a solid clinical foundation in 2021 with initial data from our ongoing first-in-human trial of KIN-2787 expected in the third quarter of 2022 and are pleased to announce that we will be expanding the trial to include patients with NRAS-mutant melanoma both in monotherapy and in combination with binimetinib," said Nima Farzan, Chief Executive Officer of Kinnate. “We are leveraging the power of the Kinnate Discovery Engine to potentially improve outcomes of cancer patients and overcome the limitations of current targeted therapies. Our goal is to generate one IND filing a year and in 2022 we expect Phase 1 initiation for our second program, KIN-3248, a Fibroblast Growth Factor Receptor inhibitor candidate, in the first half of the year subject to IND clearance by the FDA.”

NRAS-mutant melanoma is an adjacent population to RAF-driven solid tumors where signaling is highly CRAF-dependent. Approved BRAF inhibitors that target BRAF Class I alterations are not effective in NRAS-mutant melanoma. Currently there is no approved targeted therapy approved for this population. The company’s preclinical data supports development of KIN-2787 in combination with binimetinib in NRAS-mutant melanoma. In vitro data indicates meaningful and synergistic combination benefit of KIN-2787 with binimetinib in NRAS-mutant melanoma cells. In in vivo xenograft models of NRAS-mutant melanoma, treatment with KIN-2787 in combination with binimetinib was well tolerated and resulted in significant tumor growth inhibition, including tumor regressions at clinically relevant twice-daily (BID) doses of KIN-2787 and binimetinib, respectively. The addition of NRAS-mutant melanoma patients meaningfully expands the potential market opportunity for KIN-2787 as the NRAS-mutant melanoma population represents approximately 25% of advanced and metastatic melanoma patients and is largely discrete from those melanoma patients with BRAF Class I, II or III alteration-driven disease.

Key 2021 Highlights


In collaboration with Guardant Health, announced initial findings from a BRAF kinase alteration genomic landscape and real-world clinical outcomes study with preliminary analyses suggesting that the prevalence of Class II and III alterations across patients with advanced and metastatic solid tumors is higher than previously understood. Among the nearly 6,000 patients who were identified as having BRAF alteration-positive cancers, approximately 55% were found to be harboring Class II and III alterations in over 25 common adult solid tumors, including Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer, Prostate Cancer and Breast Cancer.



Announced the first patient dosed in a Phase 1 trial evaluating KIN-2787 and detailed the two-part Phase 1 trial design for KN-8701 (NCT04913285), a first-in-human, multicenter, non-randomized, open-label, Phase 1 trial of KIN-2787 in adult patients with BRAF-mutant advanced and metastatic solid tumors.


Presented data at major medical meetings including:

o
details of the two-part Phase 1 trial design for KN-8701 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics;

o
preclinical data on the KIN-3248 program at the JCA-AACR Precision Cancer Medicine International Conference; and

o
preclinical data from the KIN-2787 program at American Society of Clinical Oncology (ASCO) Annual Meeting.


Closed a $35 Million Series A financing to establish a Chinese joint venture, Kinnjiu Biopharma Inc. (“Kinnjiu”), led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital. Kinnjiu has an exclusive license to develop and commercialize Kinnate’s currently most advanced kinase inhibitor candidates in Greater China.


Expanded the organization to 61 full-time employees as of December 31, 2021, of which 46 were engaged in research and development activities, and announced key appointments to the Board of Directors and executive team.


Announced the addition of Kinnate to the NASDAQ Biotechnology Index and the Russell 2000® Index.

Key Upcoming 2022 Milestone Targets

KIN-2787 Program

Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022.

Initiation of the combination portion of KN-8701 to study KIN-2787 with binimetinib in NRAS-mutant melanoma expected in the first half of 2022 with initial data expected by year end 2022.

Initiation of a Phase 1 trial in Greater China by Kinnjiu expected in mid-2022.

KIN-3248 Program

Initiation of a Phase 1 trial expected in the first half of 2022 subject to Investigational New Drug (“IND”) clearance by the U.S. Food and Drug Administration (“FDA”).

Early Discovery Pipeline

Goal to generate one IND filing a year from the Kinnate Discovery Engine.

Announcement of the next pipeline target expected in the second half of 2022.

Financial


Updated cash, cash equivalents and investments as of December 31, 2021 of approximately $324.9 million (exclusive of Kinnjiu’s cash), which is expected to fund current operations, including initiation of multiple registrational studies, into the second half of 2023.

About Kinnate
Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors. For more information, please visit www.kinnate.com.


Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. These forward-looking statements include, without limitation, statements regarding the planned expansion of KN-8701 in NRAS-mutant melanoma patients in monotherapy and in combination with binimetinib; the potential benefits of the Kinnate Discovery Engine, KIN-2787 (including in combination with binimetinib) and our other product candidates; the planned initiation of a Phase 1 trial in Greater China; the planned initiation of a Phase 1 trial for KIN-3248; our to generate one IND filing a year; the potential market opportunity for KIN-2787; the expected timing of clinical data from KN-8701; the planned announcement of an additional pipeline target; the period over which we estimate our existing cash, cash equivalents and investments will be sufficient to fund our operations; and statements by our Chief Executive Officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are also intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends. Such expectations and projections may never materialize or may prove to be incorrect. These forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors, including risks related to recently transitioning to operating as a clinical-stage biopharmaceutical company with a limited operating history; our ability to raise additional capital to finance our operations; our ability to discover, advance through the preclinical and clinical development of, obtain regulatory approval for and commercialize our product candidates; the novel approach we are taking to discover and develop drugs; our ability to timely file and obtain approval of investigational new drug applications for our planned clinical trials; the potential for any clinical trial results to differ from our preclinical study results; negative impacts of the COVID-19 pandemic on our business, including ongoing and planned clinical trials and ongoing and planned preclinical studies; competition in our industry; regulatory developments in the United States and other countries; our ability to attract, hire and retain highly skilled executive officers and employees; difficulties in managing our growth; our ability to protect our intellectual property; reliance on third parties to conduct our preclinical studies and any ongoing or planned future clinical trials, and to manufacture our product candidates; general economic and market conditions; and other risks.

These and other risks, uncertainties, assumptions and other factors are further described under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 that we have filed with the Securities and Exchange Commission (the “SEC”), as well as in our subsequent filings we make with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. Investors should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Our forward-looking statements speak only as of the date of this release, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason in the future.

Contacts:

Investors:
Patti Bank
ICR Westwicke
415-513-1284
investors@kinnate.com

Media:
Colin Sanford
colin@bioscribe.com
 


EX-101.SCH 3 knte-20220106.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 knte-20220106_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 knte-20220106_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 image00001.jpg begin 644 image00001.jpg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htm IDEA: XBRL DOCUMENT v3.21.4
Document and Entity Information
Jan. 06, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 06, 2022
Entity Registrant Name KINNATE BIOPHARMA INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39743
Entity Tax Identification Number 82-4566526
Entity Address, Address Line One 3611 Valley Centre Drive
Entity Address, Address Line Two Suite 175
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 858
Local Phone Number 299-4699
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001797768
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol KNTE
Security Exchange Name NASDAQ
XML 8 brhc10032606_8k_htm.xml IDEA: XBRL DOCUMENT 0001797768 2022-01-06 2022-01-06 false 0001797768 8-K 2022-01-06 KINNATE BIOPHARMA INC. DE 001-39743 82-4566526 3611 Valley Centre Drive Suite 175 San Diego CA 92130 858 299-4699 false false false false Common Stock, par value $0.0001 per share KNTE NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://kinnate.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10032606_8k.htm brhc10032606_ex99-1.htm knte-20220106.xsd knte-20220106_lab.xml knte-20220106_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10032606_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10032606_8k.htm" ] }, "labelLink": { "local": [ "knte-20220106_lab.xml" ] }, "presentationLink": { "local": [ "knte-20220106_pre.xml" ] }, "schema": { "local": [ "knte-20220106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "knte", "nsuri": "http://kinnate.com/20220106", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10032606_8k.htm", "contextRef": "c20220106to20220106", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://kinnate.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10032606_8k.htm", "contextRef": "c20220106to20220106", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://kinnate.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001140361-22-000828-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-000828-xbrl.zip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end